Francesco Conte reviews JP Morgan European Discovery Trust (JEDT) AGM 2023

Francesco Conte reviews JP Morgan European Discovery Trust (JEDT) AGM 2023

JP Morgan European Discovery Trust plc (LON:JEDT) Co-Portfolio Manager and Managing Director, Francesco Conte presents a review of the European investment trust at the AGM in July 2023. The video contains a detailed review of the investment performance of the trust, a summary of investment approach and recent activity and outlook.

JPMorgan European Discovery Trust plc (LON:JEDT) is an investment trust company. The Investment Trust JEDT objective is to achieve capital growth from a portfolio of quoted smaller companies in Europe, excluding the United Kingdom.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

JPMorgan European Discovery Trust (JEDT) Latest Research, January 2026

Since taking over in March 2024, JEDT’s new management team has strengthened performance while positioning the portfolio for volatile market conditions.

Investors are returning to Europe’s broadest index

The STOXX 600 has passed 600 for the first time as investors rotate into stable earnings and real assets across Europe.

JPMorgan European Discovery Trust November Factsheet 2025

As at 30 November 2025, the Trust reported net assets of £651.5 million, positive longer term performance against its benchmark, and a diversified portfolio positioned to benefit from recovery and growth across European smaller companies.

Europe stocks climb as banks and energy shift the narrative

European stocks are climbing as banks and energy lead a selective investor rotation into cash-generative sectors.

Europe stocks climb as renewables react to US permit decision

Europe stocks climbed as a US court decision opened the door for renewable firms to regain momentum across international markets.

Fresh signals from Europe as capital repositions

European markets show renewed sector rotation as investors favour banks and respond to stock-specific catalysts like Bayer’s legal breakthrough.

Search

Search